Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Pharmaceutical
Geropharm, one of Russia’s top drugmakers, plans to become one of the leading producers and suppliers of insulin in the Latin American region in years to come. 11 June 2019
Pharmaceutical
Russian financial conglomerate Sistema PJSFC is accelerating expansion in the domestic pharmaceutical business through the acquisition from the investment company Marathon Group of two domestic pharmaceutical companies: Sintez and Biocom, reports The Pharma Letter’s local correspondent. 11 June 2019
Biotechnology
Despite a perceived lack of innovation that has moved the needle in the last five years, rheumatology remains a massively lucrative sector in which many of the world’s biggest pharma companies continue to earn the largest slice of their revenue. 7 June 2019
Biotechnology
As the dust settles on this year’s annual meeting of the American Society of Clinical Oncology (ASCO), analysts have a lot of promising data to digest. 7 June 2019
Pharmaceutical
An important player in the global fight against AIDS, India has called for expanding antiretroviral therapy coverage to combat HIV/AIDS. Emphasising the importance of continued political commitment, a senior diplomat has said competing financing demands and changing priorities should not affect efforts to provide adequate resources to fight HIV/AIDS, reports The Pharma Letter’s India correspondent. 6 June 2019
Pharmaceutical
Patients must always be the center around which the entire innovation process revolves, while seeking to satisfy unmet patient needs, writes Alfredo Barón de Juan, Executive Vice President, Global Commercial Operations at Almirall, in an Expert View piece. 5 June 2019
Generics
Baltpharma, one of Russia’s leading drugmakers has announced its plans to invest about 2.1 billion roubles (~$32 million) in the building of a new plant for the production of active pharmaceutical ingredients (APIs) in the Russian St Petersburg region. 3 June 2019
Pharmaceutical
Mere statistics cannot describe the changes that have taken place, and are taking place, between employees and their employers in Japan’s pharma companies, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter. 31 May 2019
Pharmaceutical
“If Congress weakens patent laws, patients may never benefit from new treatments or cures." 30 May 2019
Pharmaceutical
The authorities of Russia’s Moscow region plan to organize a tender for the supplies of certain vital drugs for the needs of local customers, according to the press-service of the government of the Moscow region. 30 May 2019
Pharmaceutical
The Russian government is considering providing additional legal and legislative support for domestic drugmakers in their patent disputes with foreign competitors, according to recent statements by some senior officials from the Russian Ministry of Health and some leading local drugmakers. 29 May 2019
Biosimilars
As generic prices continue to slide, specialty drugs and biologics are the flavor of the season in India. Several drugmakers are following a differentiated market approach, with some players getting into manufacturing and distribution of complex range of products, reports The Pharma Letter’s India correspondent. 28 May 2019
Biotechnology
Investors stand to play a crucial role in driving healthcare sustainability as well as supporting scientific innovation, write Nathalie Flury and Michael Schröter, founding partners at Swiss asset manager Viopas Partners, and Kate Dion, healthcare value communications consultant at 3D Communications, in an Expert View piece. 24 May 2019
Pharmaceutical
Japanese pharma Daiichi Sankyo has denied that it is negotiating the sale of its subsidiary, Daiichi Sankyo Healthcare, despite media reports that talks are underway. 24 May 2019
Biotechnology
As industry majors prepare to make a splash at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), 2003-founded nanomedicine specialist Nanobiotix hopes it can punch above its weight. 24 May 2019
Biotechnology
It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now almost upon us, with the event due to start in Chicago on Friday, May 31. 22 May 2019
Pharmaceutical
The Russian government predicts the domestic pharmaceutical market will more than double within the next decade, which, however, will mainly depend on the successful implementation of the existing state strategy in the field of pharmaceutics, which is designed until 2030, according to recent statements of Russia’s first deputy minister of industry and trade Sergey Tsyb, report The Pharma Letter’s local correspondent. 22 May 2019
Biotechnology
As China is becoming an incubator for an increasing number of innovative biotech startups, multinationals are actively seeking potential novel assets to enrich their global pipelines, said speakers at the ChinaBio forum held recently in Shanghai, reports The Pharma Letter’s local correspondent Wang Fangqing. 20 May 2019
Generics
The retail price of nine anti cancer drugs have been slashed by up to 87% in India by the National Pharmaceutical Pricing Authority. 20 May 2019
Biotechnology
When it comes to long-term investment in pharma stocks, looking at pipeline assets at a pre-clinical or early clinical stage gives as good a clue as any as to where the value lies. 17 May 2019
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze